Figure 2.
Meta-analysis forest plots. (A) Meta-analysis of mean difference of change in monthly migraine days of galcanezumab 120 mg versus placebo and (B) meta-analysis of mean difference of change in monthly migraine days of galcanezumab 240 mg versus placebo.
(A) Change in monthly migraine days – mean difference of galcanezumab 120 mg versus placebo.
(B) Change in monthly migraine days – mean difference of galcanezumab 240 mg versus placebo.
